The FDA currently collects information on active pharmaceutical ingredients (APIs) and final drug fill and finish (FDFs) manufacturing sites when collecting GDUFA user fees, including the use and identity of Contract Manufacturing Organizations (CMOs) from ANDA sponsors. Without imposing additional respondent burden on ANDA sponsors, the FDA could provide a valuable service by making this information public. This need not involve disclosure of any monetary/financial details of these arrangements.
Read Full Article »
